PRADHAN MANTRI BHARTIYA JANAUSHADHI PARIYOJANA (PMBJP)

20 Nov 2026

Tags: Social Justice   Social Services   Health sector issues

Source: The Hindu

Context: The Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) has improved access to affordable generic medicines. However, limited public awareness, concerns regarding quality, inconsistent availability and inadequate funding continue to restrict its potential to reduce households' healthcare expenditure.

About Pradhan Mantri Bhartiya Janaushadhi Pariyojana

  • Launch: Initially launched in 2008 and revamped in 2015 to provide quality generic medicines at affordable prices.
  • Implementing agency: Pharmaceuticals and Medical Devices Bureau of India (PMBI), under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilisers.
  • Delivery mechanism: Medicines are made available through dedicated retail outlets called Jan Aushadhi Kendras (JAKs).
  • Product coverage: The scheme covers 2,110 medicines and 315 surgical items.
  • Objectives: Reduce out-of-pocket healthcare expenditure, promote generic medicines, improve access to essential medicines and strengthen affordable healthcare.

Performance and Achievements

  • Expansion of outlets: Jan Aushadhi Kendras increased from 17,990 (December 2025) to 20,547 (July 2026), against a target of 25,000 outlets by March 2027.
  • Public reach: Government estimates indicate approximately 10–12 lakh visitors daily.
  • Sales: Medicines worth ₹2,252 crore (at maximum retail price) were sold during FY 2025–26.
  • Household savings: Estimated savings were approximately ₹9,000 crore in FY 2025–26 and ₹45,000 crore over 12 years.
  • Affordability: Medicines are estimated to be approximately 80% cheaper than corresponding market-priced medicines, substantially reducing household medical expenditure.

Major Challenges in Expanding PMBJP

  • Limited Geographical Reach and Public Awareness
    • Low outlet penetration: Despite 20,547 Kendras, their number remains small compared with approximately 12 lakh chemists and druggists reported by the Chemists' Association. This is a comparison of scale, not an exact estimate of national outlet coverage.
    • Location disadvantage: Some Kendras may operate in less commercially active locations to minimise rental costs, reducing their visibility and accessibility.
    • Awareness deficit: A small study of 200 outpatients in Port Blair found that only one-third had heard of the scheme, while more than half were unaware of the products sold. This is indicative rather than nationally representative evidence.
    • Social perception: Some people perceive Jan Aushadhi Kendras as outlets exclusively meant for economically weaker sections, discouraging wider adoption.
  • Limited Acceptance of Generic Medicines
    • Prescription practices: Patients generally depend on doctors to decide the medicine's generic composition, active ingredients, strength and dosage.
    • Regulatory challenge: The National Medical Commission's directive requiring doctors to prescribe medicines using generic names faced opposition from doctors' bodies citing concerns over professional autonomy, accountability and quality; its implementation was put on hold.
    • Low consumer demand: Only 6% of patients in the Port Blair study had ever asked doctors for generic medicines.
    • Need for trust: Greater awareness among both doctors and patients is essential to increase acceptance of generic medicines.
  • Quality Concerns and Trust Deficit
    • Quality assurance: Suppliers are required to possess WHO-GMP certification, and every batch of medicines is required to undergo testing.
    • Reported quality: Government-reported substandard medicine rates stand at 0.34% for Jan Aushadhi medicines compared with 3.70% in the open market.
    • Transparency concerns: The period, testing methodology and number of batches tested are not clearly specified in the reported comparison. A 2020 report also recorded 106 batches recalled over four years without indicating the total batches tested.
    • Way forward: Independent testing, transparent reporting and publicly available quality data are essential to build confidence among doctors and consumers.
  • Inconsistent Availability of Medicines
    • Stock shortages: Reports of Kendras running out of medicines and inconsistent availability of certain products discourage repeat purchases.
    • Vicious cycle: Stock shortages reduce consumer trust and footfall, weakening sales and the capacity of outlets to maintain adequate inventories.
    • Need for measurement: Actual stock availability and unmet consumer demand must be systematically monitored before designing corrective interventions.
  • Limited Public Participation
    • Universal adoption: Jan Aushadhi should be promoted as an affordable medicine option for all income groups rather than a welfare outlet exclusively for the poor.
    • Demand-driven expansion: Wider consumer participation can increase sales, encourage better stocking, improve economies of scale and incentivise manufacturers to expand production.
    • Manufacturing advantage: India's strong generic medicine manufacturing base, which supplies approximately one-fifth of global generic medicines, provides an opportunity to support greater demand.

Way Forward: Measures to Strengthen PMBJP

  • National-level assessment: The Department of Pharmaceuticals and Ministry of Health should commission an independent, nationally representative survey with qualified academic institutions to examine public awareness, consumer perceptions, doctors' prescribing practices, medicine availability and reasons for non-utilisation.
  • Transparent quality assurance: The Indian Pharmacopoeia Commission (IPC) has agreed to conduct random testing of medicines from Jan Aushadhi outlets. Results should be published regularly, specifying the testing period, methodology and laboratories.
  • Digital stock management: Introduce an online inventory-tracking system with dynamic reordering to minimise stockouts and ensure consistent availability of medicines.
  • Engaging medical professionals: Once quality is consistently demonstrated, engage doctors' associations to restore confidence in generic prescribing. Displaying bioequivalence status on medicine labels can further improve trust.
  • Public awareness campaigns: Promote Kendras as affordable medicine outlets for all through social media, targeted advertisements and wider adoption of the Jan Aushadhi Sugam App.
  • Strengthening Jan Aushadhi Sugam: The app already provides store locations, contact numbers, navigation through Google Maps and medicine-wise price lists. Adding real-time medicine stock information can improve its utility.
  • Dedicated financial support: Increase government health expenditure and provide dedicated funding for expanding and promoting Jan Aushadhi Kendras.

Additional Relevant Information for UPSC

Generic Medicines and Bioequivalence

  • Generic medicines: Medicines containing the same active pharmaceutical ingredient, strength and dosage form as their corresponding reference or branded medicines, generally sold at lower prices.
  • Bioequivalence: Two pharmaceutical products are bioequivalent when they demonstrate comparable rates and extents of absorption of the active ingredient under specified conditions.
  • Significance: Ensures therapeutic equivalence and builds confidence among doctors and patients regarding generic medicines.
  • WHO-GMP: World Health Organization's Good Manufacturing Practices provide standards to ensure consistent pharmaceutical quality, safety and manufacturing processes.

Out-of-Pocket Expenditure (OOPE) on Healthcare

  • Meaning: Healthcare expenditure paid directly by households at the point of receiving medical services, without reimbursement.
  • Medicine expenditure: Medicines account for approximately 60–70% of household OOPE on health in India, making affordable medicines critical for financial protection.
  • Insurance gap: Outpatient medicine expenses are largely not covered under standard health insurance schemes such as Ayushman Bharat–Pradhan Mantri Jan Arogya Yojana (AB-PMJAY).
  • Government health expenditure: Stood at 1.43% of GDP in 2023–24, below the National Health Policy 2017 target of 2.5% of GDP by 2025.
  • Policy implication: Expanding affordable medicine access can reduce household healthcare costs while broader public health financing is strengthened.

Conclusion: PMBJP has demonstrated the potential of affordable generic medicines to reduce household healthcare expenditure. However, its expansion requires greater public awareness, transparent quality assurance, reliable medicine availability, doctors' participation and dedicated government funding. Strengthening the scheme can make affordable healthcare more accessible and advance the goal of Universal Health Coverage (UHC) in India.